RefleXion guided lung radiotherapy designated 'breakthrough'

RefleXion Medical's biology-guided radiotherapy has received a breakthroug...Read more on AuntMinnie.comRelated Reading: RefleXion to showcase tech, abstracts at ASTRO 2021 Lantheus, RefleXion to collaborate on prostate cancer treatment RefleXion to install X1 at cancer center in Texas RefleXion raises another $40M, mulls Asia strategy RefleXion, Telix partner on high-risk cancer treatments
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

ConclusionWe observed strong reproducibility in the assessment of PI-QUAL between two radiologists with high expertise in prostate mpMRI. At present, PI-QUAL offers clinicians the only available tool for evaluating and reporting the quality of prostate mpMRI in a systematic manner but further refinements of this scoring system are warranted.Key Points•Inter-reader agreement for each single Prostate Imaging Quality (PI-QUAL) score (i.e., PI-QUAL 1 to PI-QUAL 5) was strong, with weighted kappa = 0.85 (95% confidence intervals: 0.51 – 1) and percent agreement = 84%.• Interobserver  agreement was strong wh...
Source: European Radiology - Category: Radiology Source Type: research
Prostate Cancer and Prostatic Diseases, Published online: 28 January 2022; doi:10.1038/s41391-021-00334-3Prostate Cancer: a comparison of focal therapy and radical prostatectomy
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Source: Patient Preference and Adherence - Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research
Proc IEEE Int Symp Biomed Imaging. 2021 Apr;2021:877-881. doi: 10.1109/isbi48211.2021.9433879. Epub 2021 May 25.ABSTRACTMulti-parametric MRI (mpMRI) is a powerful non-invasive tool for diagnosing prostate cancer (PCa) and is widely recommended to be performed before prostate biopsies. Prostate Imaging Reporting and Data System version (PI-RADS) is used to interpret mpMRI. However, when the pre-biopsy mpMRI is negative, PI-RADS 1 or 2, there exists no consensus on which patients should undergo prostate biopsies. Recently, radiomics has shown great abilities in quantitative imaging analysis with outstanding performance on co...
Source: Proceedings - International Symposium on Biomedical Imaging - Category: Radiology Authors: Source Type: research
CONCLUSIONS: Augmented PSA response analysis requires no additional data to be collected and can be performed easily using available software. It improves precision of estimation to a degree that is equivalent to a substantial sample size increase. The implication of this work is that prostate cancer trials using PSA response as a primary endpoint could be delivered with fewer participants and, therefore, more rapidly with reduced cost.PMID:35081926 | DOI:10.1186/s12885-022-09227-7
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
Clin Nucl Med. 2022 Jan 25. doi: 10.1097/RLU.0000000000004080. Online ahead of print.ABSTRACT18F-fluciclovine, a radiolabeled amino acid analog, has been approved by US Food and Drug Administration for detecting lesions of biochemical recurrence of prostate adenocarcinoma with PET/CT. However, it is not specific for prostate cancer and has been found to be present in variety of malignant and benign etiologies. We herein present an interesting case of the incidental finding of increasing uptake of 18F-fluciclovine related to intramuscular injection of antiandrogen.PMID:35085174 | DOI:10.1097/RLU.0000000000004080
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
We present the case of a 60-year-old man with medullary thyroid carcinoma and hepatic, osseous, and lymph node metastases who underwent peptide receptor radionuclide therapy with 177Lu-DOTATOC. After 2 cycles, 68Ga-DOTATOC PET/CT revealed multiple nonavid lesions. To assess whether the patient would be eligible for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, a PSMA PET/CT was conducted. PSMA PET/CT identified increased PSMA expression in both 68Ga-DOTATOC-avid and nonavid lesions. As such, dual-radiotracer PET/CT may allow for insights into the complexities of tumor heterogeneity in patients wit...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
J Appl Clin Med Phys. 2022 Jan 27:e13539. doi: 10.1002/acm2.13539. Online ahead of print.ABSTRACTVarian Ethos, a new treatment platform, is capable of automatically generating treatment plans for initial planning and for online, adaptive planning, using an intelligent optimization engine (IOE). The primary purpose of this study is to assess the efficacy of Varian Ethos IOE for auto-planning and intercompare different treatment modalities within the Ethos treatment planning system (TPS). A total of 36 retrospective prostate and proximal seminal vesicles cases were selected for this study. The prescription dose was 50.4 Gy i...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: The Gleason Grading revisions have improved PCa death prediction, likely due to classifying cribriform patterns, rather than poorly formed glands, as Gleason 4. Comedonecrosis, HGPIN and number of cores with ≥50% cancer further improve PCa death discrimination slightly.PMID:35082531 | PMC:PMC8784949 | DOI:10.2147/CLEP.S339140
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Prostate Cancer | Radiology